Finance

How Is CMS Modernizing the Healthcare Technology Ecosystem?
Data and Information How Is CMS Modernizing the Healthcare Technology Ecosystem?

The sheer scale of administrative waste in the American medical system has reached a point where the cost of moving data often exceeds the cost of the actual clinical care provided to the patient. As the nation navigates the complexities of a post-pandemic digital landscape, the Centers for

Rising ACA Premiums and Subsidy Cuts Fuel Political Tensions
Business Rising ACA Premiums and Subsidy Cuts Fuel Political Tensions

The delicate equilibrium of the American healthcare landscape has reached a precarious tipping point as the expiration of temporary federal enhancements leaves millions of families grappling with unprecedented insurance costs. While the Affordable Care Act was designed to provide a reliable safety

Can Remote Patient Monitoring Validate Lifestyle Medicine?
Data and Information Can Remote Patient Monitoring Validate Lifestyle Medicine?

The fundamental disconnect in modern healthcare remains the staggering reality that chronic disease management is dictated by daily choices made at home, yet clinical oversight is restricted to infrequent office visits. This temporal and spatial gap creates a persistent barrier to effective

Can AI and Health IT Solve the Clinician Burnout Crisis?
Technology Can AI and Health IT Solve the Clinician Burnout Crisis?

The modern healthcare professional is currently navigating a sea of digital noise that often feels more like an anchor than a life vest. While the industry has successfully transitioned from paper to pixels, this digital evolution has inadvertently created a secondary pandemic of cognitive

Are ACA Benefits Driving Up the Cost of American Healthcare?
Business Are ACA Benefits Driving Up the Cost of American Healthcare?

As the American healthcare landscape navigates the complexities of 2026, the expiration of pandemic-era financial cushions has thrust the Affordable Care Act back into the center of a high-stakes national debate over whether mandated benefits are truly sustainable. The political and economic

Aldeyra Faces Third FDA Rejection for Dry Eye Drug
Public Policy Aldeyra Faces Third FDA Rejection for Dry Eye Drug

The pharmaceutical landscape often witnesses intense regulatory friction, but the persistent struggle of Aldeyra Therapeutics to secure approval for its dry eye candidate, reproxalap, highlights a particularly challenging journey within the biotech industry. For the third time in as many years, the

Loading

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later